A price cap has been set for the Russian vaccine used in bladder cancer immunotherapy. According to the State Register of Medicines, the cost of a pack containing two doses of Imuron-Vac will be slightly less than 2,200 rubles.
Imuron-Vac, developed by the Gamaleya Center of Epidemiology and Microbiology, was registered by the Ministry of Health in June. In August, the center’s director, Aleksandr Gintsburg, reported that the vaccine is already being actively used in post-operative therapy for cancer patients. According to him, there is high demand for the new product in CIS countries, particularly in Armenia.
The vaccine stimulates the immune system and has antitumor activity. Live mycobacteria of the BCG-1 vaccine strain, introduced directly into the bladder, act as a non-specific immunomodulator, triggering a strong local response involving T-lymphocytes, macrophages, and cytokines aimed at destroying cancer cells. Imuron-Vac is used in urology for immunotherapy of superficial bladder cancer and for preventing bladder cancer recurrence after transurethral tumor resection.
